# Shorter exclusivity for later-in-class drugs without added benefit

Source: https://onco.cc/ideas/idea-fund-benefit-indexed-exclusivity/  
OnCo record `idea-fund-benefit-indexed-exclusivity` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The fifth PD-1 antibody that is no better than the first should not get the same market protection as the first. Exclusivity would shrink for copies that add nothing.

## Summary

The mirror image of value-based extension: for the third and subsequent entrants in a mechanistic class, regulatory data exclusivity is reduced (for example from eight to four years) unless a head-to-head trial demonstrates superiority or a clinically meaningful advantage (toxicity, route, population) graded on a public scale such as ESMO-MCBS. This does not block approval, which remains safety- and efficacy-based, but changes the return profile of me-too development so that capital moves to unmet needs. Capital diverted from copies is the point; the risk is reduced price competition within class, which can be offset by an abbreviated pathway for biosimilar-like entrants.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Benefit-indexed exclusivity reduces the number of later-in-class oncology programmes entering phase 3 without a superiority design by at least a third within five years and increases the share of pipeline assets on novel targets.
- Rationale: Portfolio analyses document a dozen or more checkpoint inhibitors and TROP2 ADCs in parallel development, each expecting a share of the same market. Firms respond to exclusivity rules (orphan and paediatric exclusivity changed behaviour rapidly), so trimming reward for redundancy should redirect investment.
- Proposed test: Simulate the rule against the past decade of approvals to estimate affected products, consult industry, and legislate a sunset pilot with pre-registered indicators of pipeline composition.
- Maturity: speculative
- Actor: policy

## Sources

- Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022): https://doi.org/10.1038/d41573-022-00030-4

## Connected records

- ideas: [An abbreviated approval path for follow-on antibodies within a validated class](https://onco.cc/ideas/idea-fund-abbreviated-pathway-me-too-biologics/), [Patent term extension scaled to proven survival gain](https://onco.cc/ideas/idea-fund-value-based-patent-extension/), [Require head-to-head trials against the best in class for later entrants](https://onco.cc/ideas/idea-fund-head-to-head-mandate/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- key papers: [Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape](https://onco.cc/key-papers/paper-upadhaya-nat-rev-drug-discov/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-benefit-indexed-exclusivity.json